Health
Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer Subgroup – Cancer Network
Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr…
Second-line treatment with nivolumab (Opdivo) plus paclitaxel showed clinical activity and a manageable safety profile in patients with Epstein-Barr virusrelated, microsatellite instabilityhigh (MSI-H)/mismatch repair deficient (dMMR) or PD-L1positive advanced gastric cancer, according to findings from a phase 1/2 study (NCT02951091) presented during Week 1 of the virtual AACR Annual Meeting 2021.1
At a median follow-up of 10.8 months, data from the phase 2 cohort (n = 48) showed that the combination…
-
Business21 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General21 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General21 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News7 hours agoCommissioner thanks police officer who threw a speed radar at a car